Analyst Activity – Leerink Swann Reiterates Outperform on Alexion Pharmaceuticals (NASDAQ:ALXN)

114

Analyst Ratings For Alexion Pharmaceuticals (NASDAQ:ALXN)

Today, Leerink Swann reiterated its Outperform rating on Alexion Pharmaceuticals (NASDAQ:ALXN).

There are 6 hold ratings, 17 buy ratings on the stock.

The current consensus rating on Alexion Pharmaceuticals (NASDAQ:ALXN) is Buy (Score: 2.74) with a consensus target price of $168.81 per share, a potential 38.28% upside.

Some recent analyst ratings include

  • 3/20/2017-Leerink Swann Reiterated Rating of Outperform.
  • 3/1/2017-Instinet initiated coverage with a Buy rating.
  • 3/1/2017-Nomura initiated coverage with a Buy rating.
  • 2/19/2017-BMO Capital Markets Reiterated Rating of Outperform.
  • 2/16/2017-Oppenheimer Holdings Inc. Reiterated Rating of Hold.
  • 2/17/2017-Credit Suisse Group AG Reiterated Rating of Buy.

Dividend information for Alexion Pharmaceuticals (NASDAQ:ALXN)

.
Recent Insider Trading Activity For Alexion Pharmaceuticals (NASDAQ:ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) has insider ownership of 4.41% and institutional ownership of 94.98%.

  • On 3/1/2017 Clare Carmichael, EVP, sold 2,179 with an average share price of $131.66 per share and the total transaction amounting to $286,887.14. View SEC Filing
  • On 3/1/2017 Heidi L Wagner, SVP, sold 994 with an average share price of $131.65 per share and the total transaction amounting to $130,860.10. View SEC Filing
  • On 3/1/2017 Leonard Bell, Director, sold 3,978 with an average share price of $131.96 per share and the total transaction amounting to $524,936.88. View SEC Filing
  • On 2/28/2017 Carsten Thiel, EVP, sold 125 with an average share price of $74.52 per share and the total transaction amounting to $9,315.00. View SEC Filing
  • On 2/28/2017 Edward Miller, SVP, sold 590 with an average share price of $131.48 per share and the total transaction amounting to $77,573.20. View SEC Filing
  • On 2/28/2017 Leonard Bell, Director, sold 2,738 with an average share price of $131.71 per share and the total transaction amounting to $360,621.98. View SEC Filing
  • On 2/27/2017 Edward Miller, SVP, sold 260 with an average share price of $131.20 per share and the total transaction amounting to $34,112.00. View SEC Filing

About Alexion Pharmaceuticals (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Recent Trading Activity for Alexion Pharmaceuticals (NASDAQ:ALXN)
Shares of Alexion Pharmaceuticals closed the previous trading session at 120.20 down -1.88 -1.54% with 2,441,178 shares trading hands.

An ad to help with our costs